Your AI-Trained Oncology Knowledge Connection!
Paul G. Richardson, MD, clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, and institute physician, Dana-Farber Cancer Institute, and RJ Corman Professor of Medicine at Harvard Medical School, discusses the preliminary data that has been reported with belantamab mafodotin (GSK2857916) in multiple myeloma.
Rakesh Popat, MD, discusses the DREAMM-1 trial and how to manage the corneal adverse events that result from belantamab mafodotin treatment in patients with relapsed/refractory myeloma.
In an era of personalized medicine in oncology, monoclonal antibodies, bispecific T-cell engagers, and CAR T-cell therapies are revolutionizing patient outcomes in multiple myeloma.
Saad Z. Usmani, MD, FACP, discusses various induction regimens and what they mean for patients with multiple myeloma.
Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses results from the phase I, dose-expansion DREAMM-1 trial in relapsed/refractory multiple myeloma.
Investigators are exploring various treatment modalities in the multiple myeloma pipeline, many of them using BCMA as a target because of its high expression on myeloma cells.
Nina Shah, MD, discusses how CAR T-cell therapy, bispecific T-cell engagers, and antibody-drug conjugates are being used to treat patients with multiple myeloma.
Thomas G. Martin, MD, provides insight into novel therapies under evaluation in relapsed/refractory multiple myeloma and the steps that need to be taken prior to and upon the use of these approaches in clinical practice.
David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.
Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorder, director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses the DREAMM-1 and DREAMM-2 trials in multiple myeloma.
